Recent Advances in Cancer Cachexia

암성 악액질의 최신 지견

  • Choi, Sang-Gyu (Department of Radiation Oncology, Dankook University College of Medicine)
  • 최상규 (단국대학교 의과대학 방사선종양학과)
  • Received : 2010.10.27
  • Accepted : 2011.01.12
  • Published : 2011.02.28


Purpose: The study was aimed to review and understand the meaning of cancer cachexia. Methods: Using the keywords "cachexia" and "cancer cachexia" 30 oncology research published from 1974 to 2009 were selected for the review. Results: The mechanism of cancer cachexia has not been fully understood, but various pathogenesis appears to be involved in the development cachexia including altered metabolism of carbohydrate, lipid, and protein associated with cytokines and hormone. As a result, muscle strength, food intake and resting energy expenditure (REE) are reduced. Most medications for the treatment of cachexia show debating results except some drugs such as megace. Supportive care including nutritional education, nursing care, and social support are found another effective treatment options. Conclusion: The results of this study would help oncology nurses to understand the mechanism of cancer cachexia and its management.


Supported by : 단국대학교


  1. Larkin M. Thwarting the dwindling progression of cachexia. Lancet 1998; 351:1336.
  2. Bruera E. Anorexia, cachexia and nutrition. BMJ 1997;315:1219-22.
  3. Slaviero KA, Read JA, Clarke SJ, Rivory LP. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 2003;46:148-57.
  4. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001;142:3292-301.
  5. Pedersen BK. Exercise immunology. New York: Chapman & Hall;1997.
  6. Perboni S, Inui A. Anorexia in cancer: role of feedeing-regulatory peptides. Phil Trans R Soc B 2006;361:1281-9.
  7. Suto G, Kiraly A, Tache Y. IL-1b inhibits gastric emptying in rats: mediation through prostaglandin and corticotropin-releasing factor. Gastroenterology 1994;106:1568-75.
  8. Nelson KA,Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213-25.
  9. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
  10. Shellock FG, Riedinger MS, Fishbein MC. Brwon adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986;111:82-5.
  11. Sanchis D, Busquets S, Alvarez B, Ricquier D, Lopez-Soriano FJ, Argiles JM. Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett 1998;436:415-8.
  12. Tisdale MJ. Metabolic abnormalities in cachexia and anorexia. Nutrition 2000;16:1013-4.
  13. Tisdale MJ. Cancer anorexia and cachexia. Nutrition 2001;17:438-42.
  14. Tisdale MJ. Protein loss in cancer cachexia. Science 2000;289:2293-4.
  15. Bozzetti F, Mariani L. Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN J Parenter Enteral Nutr 2009;33:361-7.
  16. Evans WJ, Morley JE, Argilés J, Bales C, Varacos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793-9.
  17. Body JJ. The syndrome of anorexia-cachexia. Curr Opin Oncol 1999; 11:255-60.
  18. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607-9.<1607::AID-CNCR2820330620>3.0.CO;2-V
  19. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989;25: 1823-9.
  20. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci 1999;22: 62-7.
  21. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-4.
  22. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-7.
  23. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008;30: 67-74.
  24. Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O'Mahony M, Uhrich M, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer 1999;86:684-8.<684::AID-CNCR18>3.0.CO;2-6
  25. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003;52:1479-86.
  26. Nelson KA,Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213-25.
  27. Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340-3.
  28. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005;54:540-5.
  29. Lesser GJ, Case D, Ottery F, McQuellon R, Choksi JK, Sanders G, et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. J Clin Oncol 2008;26:505s
  30. Reid J, McKenna H, Fitzsimons D, McCance T. The experience of cancer cachexia:A qualitative study of advanced cancer patients and their family members. Int J Nurs Stud 2009;46:606-16.